Literature DB >> 3323299

Nifedipine in hypertensive emergencies: a prospective study.

D Schillinger1.   

Abstract

Hypertensive emergencies usually present to the emergency department. Nifedipine was administered to 15 patients presenting to the emergency department with a diastolic blood pressure greater than 120 mm Hg with chest pain, shortness of breath, or focal neurological symptoms. Average blood pressure on entry was 215/134.9 mm Hg and decreased to 158/88 mm Hg over a two-hour period. No patient had any worsening of symptoms or suffered deleterious effects. All patients with pulmonary edema or chest pain noted prompt improvement in symptoms. One patient became hypotensive without clinical significance. Two patients failed to respond to nifedipine and were treated with nitroprusside. Nifedipine appears to be safe and effective in the management of hypertensive crises.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323299     DOI: 10.1016/0736-4679(87)90208-3

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  5 in total

Review 1.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

2.  The Role of a Single Dose of Sublingual Nifedipine in Managing Hypertensive Emergencies in the Patients who Undergo Haemodialysis.

Authors:  Jagjit Singh; Rajiv Kumar; Vitul K Gupta; Arun Kumar Maria; Rubina Paul; Simerpreet Kaur; Prabhnoor Singh Hayer
Journal:  J Clin Diagn Res       Date:  2012-12-15

Review 3.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Perioperative hypertension management.

Authors:  Joseph Varon; Paul E Marik
Journal:  Vasc Health Risk Manag       Date:  2008

Review 5.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.